CONDENSED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Total revenue	$ 4,790	$ 1,935
Operating expenses:
Cost of goods sold	2,081
Research and development	21,273	19,131
General and administrative	9,347	6,365
Total operating expenses	32,701	25,496
Operating loss	(27,911)	(23,561)
Other income, net	162	260
Net loss	$ (27,749)	$ (23,301)
Net loss per share:
Basic	$ (0.52)	$ (0.47)
Diluted	$ (0.52)	$ (0.47)
Weighted average shares:
Basic	53,507,060	49,917,990
Diluted	53,507,060	49,917,990
Other comprehensive loss, net of tax of $0:
Change in unrealized losses on available-for-sale marketable securities	$ (1,365)	$ (61)
Total comprehensive loss	(29,114)	(23,362)
Commercial Supply Revenue
Revenue:
Total revenue	$ 4,790
License and Milestone Fees
Revenue:
Total revenue		1,192
Collaborative Revenue
Revenue:
Total revenue		706
Clinical Compound Revenue
Revenue:
Total revenue		$ 37